Nocardia: Difference between revisions
From IDWiki
Nocardia
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
*Microscopic appearance similar to [[Actinomyces]], differentiated by acid fast staining ([[Actinomyces]] is ''not'' acid fast) |
*Microscopic appearance similar to [[Actinomyces]], differentiated by acid fast staining ([[Actinomyces]] is ''not'' acid fast) |
||
*Colonies are slow to grow and have a chalky white appearance |
*Colonies are slow to grow and have a chalky white appearance |
||
− | * |
+ | *Ubiquitous environmental saprophyte found in soil and water |
=== Pathophysiology === |
=== Pathophysiology === |
||
Line 14: | Line 14: | ||
* Spores or mycelia are either inhaled into the lungs or directly inoculated in the skin and soft tissue |
* Spores or mycelia are either inhaled into the lungs or directly inoculated in the skin and soft tissue |
||
* Traumatic inoculation includes during motor vehicle collisions, mild scratches or pricks, or nosocomial with dirt entering through an open wound or central line |
* Traumatic inoculation includes during motor vehicle collisions, mild scratches or pricks, or nosocomial with dirt entering through an open wound or central line |
||
+ | * Forms difficult-to-treat biofilms when involved in [[CLABSI|CLABSIs]] |
||
=== Risk Factors === |
=== Risk Factors === |
||
Line 20: | Line 21: | ||
* Among transplant recipients, [[lung transplant]] appears to be highest risk |
* Among transplant recipients, [[lung transplant]] appears to be highest risk |
||
* High-dose steroids and high levels of [[calcineurin inhibitors]] appear to be specific risk factors |
* High-dose steroids and high levels of [[calcineurin inhibitors]] appear to be specific risk factors |
||
+ | * Also diabetes and alcohol use |
||
== Clinical Manifestations == |
== Clinical Manifestations == |
||
Line 61: | Line 63: | ||
==Management== |
==Management== |
||
+ | === Further Evaluation === |
||
+ | |||
+ | * Consider screening MRI brain in all patients with disseminated or pulmonary disease regardless of neurologic symptoms |
||
+ | * Consider CT chest in all patients |
||
+ | * Consider assessment for immunodeficiency; at the very least, HIV testing and a good history |
||
+ | |||
+ | === Antimicrobial Selection === |
||
*Mild to moderate: [[Is treated by::TMP-SMX]] |
*Mild to moderate: [[Is treated by::TMP-SMX]] |
||
**Immunocompetent: 5-10 mg/kg split tid to qid |
**Immunocompetent: 5-10 mg/kg split tid to qid |
Latest revision as of 18:05, 12 March 2023
Background
Microbiology
- Beaded Gram-positive partially acid-fast bacillus within the class Actinobacteria and order Corynebacteriales
- Catalase positive and lyzozyme resistant
- Has a classic beaded branching cell morphology
- Microscopic appearance similar to Actinomyces, differentiated by acid fast staining (Actinomyces is not acid fast)
- Colonies are slow to grow and have a chalky white appearance
- Ubiquitous environmental saprophyte found in soil and water
Pathophysiology
- Spores or mycelia are either inhaled into the lungs or directly inoculated in the skin and soft tissue
- Traumatic inoculation includes during motor vehicle collisions, mild scratches or pricks, or nosocomial with dirt entering through an open wound or central line
- Forms difficult-to-treat biofilms when involved in CLABSIs
Risk Factors
- More common in immunocompromised (cell-mediated immunodeficiency including HIV, hematologic malignancy, and transplant patients), though can also occur in immunocompetent who have COPD, bronchiectasis, and cystic fibrosis
- Among transplant recipients, lung transplant appears to be highest risk
- High-dose steroids and high levels of calcineurin inhibitors appear to be specific risk factors
- Also diabetes and alcohol use
Clinical Manifestations
Primary Cutaneous
- Typically acquired by direct inoculation with soil
- Nocardia brasiliensis is the most common cause in North America
- May present with superficial soft tissue infection, including ulcer, abscess, cellulitis, pustules, plaques, or papules, most commonly on the arms and legs
- Can progress to lymphocutaneous infection with sporotrichoid lesions
Pulmonary
- Subacute or chronic cough, dyspnea, fever, with or without pleuritic chest pain
- Most common form of disease in US
- Colonization also possible, particularly with patients who have structural lung changes like cystic fibrosis
- Starts with inflammation followed by formation of granulomas and necrotic abscesses
- Imaging typically showed lung nodules, lobar consolidation, and pleural effusion, and may show infiltrates and necrotizing granulomas
- Usually bilateral
- Cavitations more common in immunocompromised patients
Disseminated
- Usually starts with a focal infection (skin or lung), which then disseminates hematogenously
- Most commonly involves skin, lungs, and CNS, but can also disseminate to kidney, joint, retina, and heart
- Much more common in immunosuppressed patients
CNS Disease
- Most common site of hematogenous dissemination
- Presents with typical symptoms of fever, headache, meningismus, seizure, and focal neurologic deficits
- Can also be asymptomatic, so immunocompromised patients should get imaging and possibly LP
Other
- Mycetoma
- Bacteremia
- Ocular infection, either from direct inoculation or hematogenous spread
- Bone and joint infection, primarily from dissemination
Management
Further Evaluation
- Consider screening MRI brain in all patients with disseminated or pulmonary disease regardless of neurologic symptoms
- Consider CT chest in all patients
- Consider assessment for immunodeficiency; at the very least, HIV testing and a good history
Antimicrobial Selection
- Mild to moderate: TMP-SMX
- Immunocompetent: 5-10 mg/kg split tid to qid
- Immunocompromised: 15 mg/kg split tid to qid
- Severe: TMP-SMX plus either amikacin or imipenem
- Other antimicrobials include ceftriaxone, minocycline, and linezolid
Duration
- Isolated cutaneous infection in immunocompetent host: 3 to 6 months
- Isolated cutaneous infection in immunocompromised host: 6 to 12 months
- Serious pulmonary infection: 6 to 12 months or longer
- Any non-cutaneous disease in immunocompromised host: at least 12 months, and possibly lifelong suppression
Monitoring
- Serial CT scans to assess response to therapy
- Monitoring for antibiotic toxicity